arecoline has been researched along with Dementia in 2 studies
Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.
arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia." | 9.05 | Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. ( Christie, JE; Ferguson, J; Glen, AI; Shering, A, 1981) |
| "25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia." | 5.05 | Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. ( Christie, JE; Ferguson, J; Glen, AI; Shering, A, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, P | 1 |
| Christie, JE | 1 |
| Shering, A | 1 |
| Ferguson, J | 1 |
| Glen, AI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| M2 Receptor Measurements in Aging and in Alzheimer's Disease[NCT00001917] | 150 participants | Observational | 1999-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for arecoline and Dementia
| Article | Year |
|---|---|
An update on the neurochemistry of Alzheimer disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Arecoline; Brain; Choline; Choline O-Acetyltransferase; Cho | 1983 |
1 trial available for arecoline and Dementia
| Article | Year |
|---|---|
Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Dementia; Dose-Response Relationship, Drug; | 1981 |